Sunshine Biopharma Inc.: INTRACOASTAL CAPITAL, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Intracoastal Capital, LLC amended its Schedule 13G stake filing for Sunshine Biopharma Inc., according to SEC accession 0001213900-26-118164. The amendment updates the investor's previously reported beneficial ownership position in the pharmaceutical company. Schedule 13G filings are required of certain institutional and passive investors, so the revision signals a change in Intracoastal's holdings or reporting status. The filing does not itself indicate a change in company fundamentals. Investors will watch for further 13G/13D amendments or Form 4 insider filings to confirm whether Intracoastal's position continues to shift.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Sunshine Biopharma Inc., Intracoastal Capital, LLC